BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 34003788)

  • 1. Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.
    Heltberg ML; Chen SH; Jiménez A; Jambhekar A; Jensen MH; Lahav G
    Cell Syst; 2019 Dec; 9(6):548-558.e5. PubMed ID: 31812692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X; Yuan ZM
    J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDMX is essential for the regulation of p53 protein levels in the absence of a functional MDM2 C-terminal tail.
    Sanford JD; Yang J; Han J; Tollini LA; Jin A; Zhang Y
    BMC Mol Cell Biol; 2021 Sep; 22(1):46. PubMed ID: 34551723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome Stability Requires p53.
    Eischen CM
    Cold Spring Harb Perspect Med; 2016 Jun; 6(6):. PubMed ID: 27252396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
    Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
    Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and Biochemical Techniques for Deciphering p53-MDM2 Regulatory Mechanisms.
    Karakostis K; López I; Peña-Balderas AM; Fåhareus R; Olivares-Illana V
    Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33396576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2: current research status and prospects of tumor treatment.
    Yao Y; Zhang Q; Li Z; Zhang H
    Cancer Cell Int; 2024 May; 24(1):170. PubMed ID: 38741108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
    Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
    Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Logic-based modeling and drug repurposing for the prediction of novel therapeutic targets and combination regimens against E2F1-driven melanoma progression.
    Singh N; Khan FM; Bala L; Vera J; Wolkenhauer O; Pützer B; Logotheti S; Gupta SK
    BMC Chem; 2023 Nov; 17(1):161. PubMed ID: 37993971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors.
    Sun SY; Crago A
    J Clin Med; 2023 May; 12(11):. PubMed ID: 37297833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting p53 pathways: mechanisms, structures, and advances in therapy.
    Wang H; Guo M; Wei H; Chen Y
    Signal Transduct Target Ther; 2023 Mar; 8(1):92. PubMed ID: 36859359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glaucocalyxin A Inhibits the Malignancies of Gastric Cancer Cells by Downregulating MDM2 and RNF6
    Liu Y; Chen P; Qi D; Chen L
    Front Oncol; 2022; 12():871169. PubMed ID: 35814430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death.
    Koo N; Sharma AK; Narayan S
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathways.
    Chen Q; Deng S; Deng M; Shi Y; Zhong M; Ding L; Jiang Y; Zhou Y; Carter BZ; Xu B
    Exp Hematol Oncol; 2022 Apr; 11(1):23. PubMed ID: 35429966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and Immunological Effects of p53-Targeting Vaccines.
    Zhou S; Fan C; Zeng Z; Young KH; Li Y
    Front Cell Dev Biol; 2021; 9():762796. PubMed ID: 34805170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2 and MdmX: Partners in p53 Destruction.
    Manfredi JJ
    Cancer Res; 2021 Apr; 81(7):1633-1634. PubMed ID: 34003788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation
    Yang J; Jin A; Han J; Chen X; Zheng J; Zhang Y
    Cancer Res; 2021 Feb; 81(4):898-909. PubMed ID: 33277368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of p53: a collaboration between Mdm2 and Mdmx.
    Pei D; Zhang Y; Zheng J
    Oncotarget; 2012 Mar; 3(3):228-35. PubMed ID: 22410433
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.